Pharma FDI in the times of Covid-19: A challenging pill to swallow
Political and economic stability, and a coherent Covid-19 containment strategy are among the key factors in attracting biopharma FDI. With supply chains disrupted and the world veering all its attention towards halting Covid-19, FDI flows into the pharmaceutical sector will strongly depend on countries’ ability to respond to the epidemic, and their overall stability.
In advance of the launch of our FDI-focused site, please complete the following survey aimed at investigating how investment plans are changing in the wake of Covid-19.
Your participation is confidential and the survey will take no longer than 5-10 minutes to complete. As a thank you we will share a copy of the survey write up with you.